- CNBC•19 hours ago
Hospital-related stocks started the week in the green following the failure of the GOP's effort to replace Obamacare.
- PR Newswire•21 hours ago
TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream from global net sales of the multiple sclerosis drug Tysabri® (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma ("RPI"). The transaction comprises a total consideration of $2.2 billion in cash and up to $650 million in royalties earned if global net sales of Tysabri® meet specific thresholds in 2018 and 2020. Perrigo's CEO John T. Hendrickson stated, "Today's announcement marks the successful outcome of our strategic alternatives process for the Tysabri® royalty stream.
- PR Newswire•4 days ago
Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of Companies, Inc.
NEW YORK, March 24, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX) Lifshitz & Miller announces investigation on behalf of PETX investors concerning PETX's statements about the commercial viability ...
PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance
Perrigo Company plc (PRGO)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||68.14 - 69.04|
|52 Week Range||66.86 - 133.53|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.81|
|Dividend & Yield||0.64 (0.94%)|
|1y Target Est||N/A|